Our top pick for
Invitae Corporation is a diagnostics & research business based in the US. Invitae Corporation shares (NVTA) are listed on the NYSE and all prices are listed in US Dollars. Invitae Corporation employs 1,900 staff and has a trailing 12-month revenue of around USD$245.5 million.
|Latest market close||USD$52.58|
|52-week range||USD$7.415 - USD$55.38|
|50-day moving average||USD$46.2311|
|200-day moving average||USD$34.7761|
|Wall St. target price||USD$46.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.874|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||2.84%|
|1 month (2020-12-17)||11.54%|
|3 months (2020-10-16)||11.80%|
|6 months (2020-07-17)||60.94%|
|1 year (2020-01-17)||167.86%|
|2 years (2019-01-17)||267.18%|
|3 years (2018-01-17)||676.66%|
|5 years (2016-01-15)||636.41%|
|Revenue TTM||USD$245.5 million|
|Gross profit TTM||USD$98.7 million|
|Return on assets TTM||-25.68%|
|Return on equity TTM||-108.42%|
|Market capitalisation||USD$8.7 billion|
TTM: trailing 12 months
There are currently 26.1 million Invitae Corporation shares held short by investors – that's known as Invitae Corporation's "short interest". This figure is 15.3% up from 22.6 million last month.
There are a few different ways that this level of interest in shorting Invitae Corporation shares can be evaluated.
Invitae Corporation's "short interest ratio" (SIR) is the quantity of Invitae Corporation shares currently shorted divided by the average quantity of Invitae Corporation shares traded daily (recently around 2.7 million). Invitae Corporation's SIR currently stands at 9.67. In other words for every 100,000 Invitae Corporation shares traded daily on the market, roughly 9670 shares are currently held short.
However Invitae Corporation's short interest can also be evaluated against the total number of Invitae Corporation shares, or, against the total number of tradable Invitae Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Invitae Corporation's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Invitae Corporation shares in existence, roughly 150 shares are currently held short) or 0.1481% of the tradable shares (for every 100,000 tradable Invitae Corporation shares, roughly 148 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Invitae Corporation.
Find out more about how you can short Invitae Corporation stock.
We're not expecting Invitae Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Invitae Corporation's shares have ranged in value from as little as $7.415 up to $55.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Invitae Corporation's is 2.1477. This would suggest that Invitae Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; and a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.